128 patients with lumbar spinal stenosis who were receiving continuous non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) were randomized to receive either a COX-2 selective NSAID (celecoxib; n=64) or a combination of an NSAID (aceclofenac) and a proton pump inhibitor (ilaprazole) (n=64). The primary outcome of interest was the severity of dyspepsia, as measured by the Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ). The secondary outcomes of interest included quality of life (Short Form 12 [SF-12]) and the incidence of adverse events. The results of this study found no significant difference between the two groups. This suggests that the combination of aceclofenac and ilaprazole does not provide any advantage over COX-2 selective NSAIDs for the mitigation of dyspepsia in lumbar spinal stenosis patients.